Business
AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor\r\n \r\n \r\n\r\n\r\nAXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor\r\n\r\n\r\n\r\n\r\n\r\nSAN DIEGO, CA - January 20, 2026 (NEWMEDIAWIRE) - AXIM Biotechnologies, Inc. (\"AXIM\" or the \"Company\") (OTC:AXIM), a diagnostic and biotechnology company advancing clinically validated solutions for ocular and inflammatory diseases, today announced the engagement of 624 Advisors, which is owned and managed by Alan J. Touch, OD, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch is considered a preeminent IVD and CDx SME and global regulatory specialist.\r\nDr. Touch brings more than three decades of global leadership across diagnostics, medical devices, pharmaceuticals, and digital health. He is the original co-inventor of the first ocular diagnostic technologies acquired by AXIM, the inventor of the world's first colored contact lens, formerly headed up Clinical Affairs at Bausch & Lomb and was Principal Strategist for Ophthalmology, Medical Devices and Diagnostics at INC Research (Syneos Health). As Chief Science Officer of an ophthalmic CDMO, he led the development of several proprietary dry eye disease (DED) products including the first eye drop based on addressing the Inflammatory Cascade through a novel pathway.  He has been a successful health care entrepreneur as well as providing senior leadership roles for major international healthcare organizations.  He founded 624 Advisors as a product development, regulatory and quality compliance consultancy. The engagement of 624 Advisors, led by Dr. Touch, provides AXIM with enhanced technical continuity, regulatory depth, and strategic execution capability at a pivotal stage of the Company's development.\r\n\"This strategic engagement is an important addition to the R&D and regulatory team at AXIM,\" said Catalina Valencia, President and CEO of AXIM Biotechnologies.  \"Dr. Touch uniquely combines inventor-level knowledge of our technology with significant senior level experience in FDA regulation, ISO quality systems, cl...